Welcome to our dedicated page for Macrogenics news (Ticker: MGNX), a resource for investors and traders seeking the latest updates and insights on Macrogenics stock.
Macrogenics Inc (MGNX) is a clinical-stage biopharmaceutical leader developing antibody-based therapies for cancer and autoimmune diseases. This page aggregates official press releases and verified news about pipeline developments, regulatory milestones, and strategic partnerships.
Investors and researchers will find timely updates on clinical trial progress, FDA designations, and collaborative research initiatives. Our curated feed includes updates on novel antibody candidates, licensing agreements, and financial disclosures—all critical for evaluating the company’s scientific and market trajectory.
Key content areas include monoclonal antibody advancements, oncology trial results, partnership announcements with pharmaceutical leaders, and quarterly earnings reports. Bookmark this page to monitor MGNX’s progress in advancing precision medicine through its proprietary antibody engineering platforms.
MacroGenics (Nasdaq: MGNX), a biopharma company specializing in monoclonal antibody-based cancer treatments, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach.
President & CEO Scott Koenig will present on June 13, 2024, at 10:00am ET. Management will also engage in one-on-one meetings. A live webcast of the presentation will be available on MacroGenics' website, with a replay accessible for 30 days post-conference.
MacroGenics, Inc. (Nasdaq: MGNX) will participate in upcoming investor conferences, including The Citizens JMP Life Sciences Conference and TD Cowen’s 5th Annual Oncology Innovation Summit. President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will be involved in fireside chats and one-on-one meetings, with webcasts available on the company's website.
MacroGenics, Inc. provides updates on corporate progress, financial results, and interim TAMARACK Phase 2 study data for vobra duo in mCRPC patients. Encouraging safety and efficacy data have led to planning for a potential Phase 3 study. Key financial results include a cash balance of $184.2 million, total revenue of $9.1 million, net loss of $52.2 million, and an extended cash runway into 2026.
MacroGenics, Inc. (Nasdaq: MGNX) will release its first quarter 2024 financial results on May 9, 2024, after the market closes. The company will host a conference call on the same day at 4:30 pm ET to discuss the results and recent corporate progress.
FAQ
What is the current stock price of Macrogenics (MGNX)?
What is the market cap of Macrogenics (MGNX)?
